Company intelligence / Profile preview

Alpine

Seattle, Washington, United States

Ownership: Public · ALPP
Employees: ~85
Development stage: Other

Overview

ALPN-101 finished Phase 1 trials in healthy volunteers with successful results and entered Phase 2 studies for lupus and graft versus host disease. ALPN-202 and ALPN-303 are advancing for cancer and B cell-mediated diseases; AbbVie licensed ALPN-101 with up to $805M in milestone payments

Therapeutic areas: ImmunologyOncology
Modalities: ProteinMonoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

AbbVie (ALPN-101 license option and collaboration)Adaptimmune Therapeutics (next-gen T cell program collaboration)Kite Pharmaceuticals (historical research and licensing for cell therapies)

Beyond the preview

Go deeper on Alpine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpine.

Explore the full profile